New Features information at Pharmaceutical Technology New and updated information from Features listed on en-us New Features information at Pharmaceutical Technology Bluerock: Canada’s stem cell contender on the journey from petri dish to clinical trial Toronto-based regenerative medicine biotech BlueRock Therapeutics was launched in December with a massive $225m series A financing. So what stem cell-based therapies is the company working on? Sun, 21 May 2017 23:00:00 GMT Micro-machines: nanotech offers new possibilities for disease detection and drug delivery For the first time, miniscule molecular machines designed for early disease detection and targeted drug delivery have been shown to work in living cells. Elly Earls meets the researchers behind the breakthrough to find out more. Wed, 17 May 2017 23:00:00 GMT Pharma Technology Focus – Issue 59 In this issue: Challenging the link between innovation and US drug pricing, the impact of Brexit on life sciences companies, a new study on the effects of cognitive-enhancing drugs, using crowdfunding to unlock cancer therapies, and more. Wed, 17 May 2017 13:58:00 GMT Challenging the link between pharma innovation and US drug pricing A new study claims to debunk the well-worn connection between inflated US drug prices and big pharma’s R&D spending. But what is the connection between innovation and pricing in the pharma space, and is it the whole story? Fri, 12 May 2017 16:12:00 GMT Brain boosters: exploring the grey area of off-label ‘smart drugs’ The growing trend for the unlicensed use of cognitive-enhancing drugs to improve performance is prompting calls for more research into the field. Has the era of brain-boosting ‘smart pills’ arrived, and what do we still need to find out about the saf… Fri, 12 May 2017 15:22:00 GMT Crowdfunding for cancer therapy The Care Oncology Clinic is crowdfunding to help provide patients access to four repurposed drugs, alongside conventional NHS cancer drug treatment therapy. Why is there a need for such a funding mechanism, and what evidence do they have to support t… Sun, 07 May 2017 23:00:00 GMT April's top stories: CN Bio licenced Hepatitis B drug programme, Astellas agreed to acquire Ogeda for €800m CN Bio licenced a Hepatitis B drug discovery programme from Bristol-Myers Squibb and Astellas Pharma agreed to acquire Belgium’s Ogeda for €800m. wraps up the key headlines from April. Mon, 01 May 2017 23:00:00 GMT Narrowing the hunt for nanoparticles Researchers from the Universities of Geneva and Fribourg have devised a rapid screening method to select the most promising nanoparticles for drug development. Lead author Inès Mottas tells Abi Millar how better access to the nanosphere could improve… Wed, 19 Apr 2017 23:00:00 GMT Pharma Technology Focus – Issue 58 In this issue: Promising Alzheimer’s drugs in development, potential applications for the hormone kisspeptin, the cost of failed drug candidates, a new app matching patients to clinical trials, pharma packaging trends, and more. Wed, 19 Apr 2017 13:56:00 GMT Pharmaceutical packaging: where should drug companies focus their efforts? The future of pharmaceutical packaging operations is far from straightforward. The Association for Packaging and Processing Technologies reveals where drug companies should be focusing their efforts. Sun, 09 Apr 2017 23:00:00 GMT Alzheimer’s drugs: will 2017 bring better news? No new Alzheimer’s drug has won approval since 2003, but the tide could soon start turning for this previously poorly understood disease. Elly Earls talks to the field’s top researchers to find out what we can expect over the next few years. Wed, 05 Apr 2017 23:00:00 GMT March's top stories: Perrigo's $2.85bn sale, Cancer Research UK's Precision Panc project Perrigo completed the sale of Tysabri drug royalty to RPI for $2.85bn, London's Institute of Cancer Research (ICR) revealed new secrets about the genetic causes of cancer, and Eli Lilly acquired CoLucid Pharmaceuticals for $960m. Pharmaceutical-techn… Sun, 02 Apr 2017 23:00:00 GMT Cancergraph: a desperately needed link between patient and clinical trial While many cancer patients are interested in clinical trials, tough eligibility criteria and a lack of information mean only a fraction actually participate. Help may be at hand, however, thanks to a new mobile app called Cancergraph, thatwhich can m… Fri, 31 Mar 2017 15:21:00 GMT Illuminating drug discovery by mapping all known drugs Innovation requires risks, but what if you could load the odds in your favour? Elly Earls meets cancer scientist Dr Bissan Al-Lazikani to find out how a new map of all existing drugs and their mechanisms of action could help the drug discovery field … Wed, 29 Mar 2017 23:00:00 GMT Pharma Technology Focus – Issue 57 In this issue: Japan’s pharma industry looks abroad, Trump’s plans for US drug manufacturing, unlocking regenerative medicine, the medical benefits of turmeric, the dangers posed by first-in-human drug trials, and more. Wed, 22 Mar 2017 14:44:00 GMT Turning to turmeric: exciting drug candidate or another dead end? Turmeric has long been used as a natural remedy, and many studies seem to back that up. However, a recent review has suggested that many of the apparent benefits are bad science. So what does that mean for turmeric research, and particularly for the … Mon, 20 Mar 2017 00:00:00 GMT BlueRock Therapeutics: Ontario’s home-grown stem cell contender New Toronto-based regenerative medicine biotech BlueRock Therapeutics was launched in December with a massive $225m series A financing from Bayer and Versant Ventures. What stem cell-based therapies is the company working on to justify this investor … Tue, 14 Mar 2017 00:00:00 GMT Takeda turns its focus overseas Japanese pharmaceutical company Takeda has bought Ariad Pharmaceuticals for around $5.2bn. Deals of this kind are becoming increasingly prevalent, as the Japanese pharma industry sets its sights beyond the traditional domestic market. Abi Millar repo… Mon, 13 Mar 2017 00:00:00 GMT Learning from tragedy: safety and dosing in first-in-human trials The Rennes clinical trial disaster in January last year highlights the dangers posed by first-in-human trials of high-risk drug candidates, with dosing strategies coming under the spotlight. What makes early-stage trials go wrong, and how can dosing … Wed, 08 Mar 2017 00:00:00 GMT February's top stories: Takeda's $5.2bn acquisition, Sanofi €270m cell culture facility investment Takeda completed its acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn, while Sanofi and Lonza invested €270m in a new mammalian cell culture facility in Switzerland. wraps up the key headlines fr… Tue, 07 Mar 2017 00:00:00 GMT